Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00364091 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis
A Phase 3 study, sponsored by Vistakon Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 365
- Enrollment target
NCT00364091 is a Phase 3 study that has completed, run by Vistakon Pharmaceuticals. The registered enrollment target is 365 participants.
The verdict
NCT00364091, a Phase 3 study, has completed, sponsored by Vistakon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 365 participants
- Enrollment target
Study Summary
The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis
Interventions
- DRUG R89674 0.025% ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2006-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00364091
The ClinicalTrials.gov registry entry for NCT00364091 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vistakon Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which R89674 0.025% ophthalmic solution is the first listed.
NCT00364091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00364091 about?
NCT00364091 is a clinical study titled "Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis". The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis
What is the current status of trial NCT00364091?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 365 participants. The study started on 2006-08.
What interventions are being tested in trial NCT00364091?
The interventions under investigation include: R89674 0.025% ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00364091?
This trial is sponsored by Vistakon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.